Clasp Therapeutics’ novel T cell engagers could offer advantages over others in this class of cancer immunotherapies. The startup is based on the research of Johns Hopkins University scientist Bert Vogelstein.
In the midst of the current measles outbreak and ongoing debates about a parent’s right to not vaccinate their children, some might wonder how bad it needs to get before legitimate requirements should be put in place. As of right now, it doesn’t seem likely that the legal system will get involved. But back in […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.